FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of pharmaceutics and medicine and deals with anticancer pharmaceutical composition or combination for prevention cancer of lungs or cancer of kidney, which contains as active ingredients medication, which is produced from gefitinib, erlotinib and soraphenib, and dihydrochloride 5-(4-(6-(4-amino-3,5-dimetylphenoxy)-1-metyl-1H-benzimidazol-2-ilmethoxy)benzyl)thiazolidine-2,4-dione.
EFFECT: invention insures increased efficiency of treatment.
16 cl, 5 dwg, 3 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOUND AND PHARMACEUTICAL COMPOSITION FOR INCREASING ANTICANCER ACTIVITY, CONTAINING SAID COMPOUND | 2019 |
|
RU2781282C1 |
| THIAZOLIDINEDIONE SALTS WITH REDUCED AFFINITY TO PPAR FOR TREATMENT OF METABOLIC DISORDERS | 2010 |
|
RU2564661C2 |
| AGENTS FOR TREATMENT AND PROPHYLAXIS OF NEOPLASMS | 2000 |
|
RU2219928C2 |
| ANTIDIABETIC OXAZOLIDINEDIONES | 2005 |
|
RU2355682C2 |
| PPAR-SUPPORTING THIAZOLIDINEDIONES AND THEIR COMBINATIONS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | 2010 |
|
RU2570424C2 |
| IMIDES BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE | 2016 |
|
RU2704807C2 |
| NEW QUINOLINE COMPOUNDS | 2018 |
|
RU2810113C2 |
| NEW METHOD FOR SYNTHESIS OF THIAZOLIDINEDIONE COMPOUNDS | 2011 |
|
RU2593370C2 |
| METHODS FOR INCREASING STABILISATION OF HYPOXYA INDUCED FACTOR-1 ALPHA | 2010 |
|
RU2521251C2 |
| THIOPHENE DERIVATIVE AND ITS USE | 2019 |
|
RU2781643C2 |
